Cargando…

Payer perceptions on the use of economic models in oncology decision making

BACKGROUND: To support oncology formulary decisions, especially with accelerated regulatory approvals and niche populations, payers desire data beyond what regulators review. Economic models showing financial impact of treatments may help, but data on payers’ use of economic models in oncology are l...

Descripción completa

Detalles Bibliográficos
Autores principales:	Biskupiak, Joseph, Oderda, Gary, Brixner, Diana, Burgoyne, Douglas, Arondekar, Bhakti, Niyazov, Alexander
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390914/ https://www.ncbi.nlm.nih.gov/pubmed/34714111 http://dx.doi.org/10.18553/jmcp.2021.27.11.1560

Ejemplares similares

Payer perceptions of the use of real-world evidence in oncology-based decision making
por: Brixner, Diana, et al.
Publicado: (2021)

Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective
por: Mistry, Rohit, et al.
Publicado: (2018)

Three Perspectives on the Impact of Comparative Effectiveness Research on Decision Making
por: Brixner, Diana I., et al.
Publicado: (2012)

RE: Cost-utility of talazoparib monotherapy treatment for locally advanced or metastatic breast cancer in Spain
por: Zou, Denise, et al.
Publicado: (2021)

Application of Decision-Analytic Models in Personalized Medicine for CML Treatment Decisions Made by Payers, Providers, and Patients
por: Saverno, Kim R., et al.
Publicado: (2012)

Cost Implications of Formulary Decisions on Oral Anticoagulants in Nonvalvular Atrial Fibrillation
por: Biskupiak, Joseph, et al.
Publicado: (2013)

“This Drug May Work, But Is It Worth the Cost?” Can Comparative Effectiveness Research Help Tame Rising Health Care Costs?
por: Brixner, Diana I., et al.
Publicado: (2012)

Introduction
por: Brixner, Diana I., et al.
Publicado: (2012)

Real-world patient-reported outcomes and physician satisfaction with poly (ADP-ribose) polymerase inhibitors versus chemotherapy in patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2–negative advanced breast cancer from the United States, Europe, and Israel
por: Mahtani, Reshma, et al.
Publicado: (2022)

Real-world study of patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2‒Negative advanced breast cancer: Patient demographics, treatment patterns, adverse events, and physician-reported satisfaction in the United States, Europe, and Israel
por: Mahtani, Reshma, et al.
Publicado: (2022)

Real-World Study of Regional Differences in Patient Demographics, Clinical Characteristics, and BRCA1/2 Mutation Testing in Patients with Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer in the United States, Europe, and Israel
por: Mahtani, Reshma, et al.
Publicado: (2022)

BRCA1/2 Mutation Testing in Patients with HER2-Negative Advanced Breast Cancer: Real-World Data from the United States, Europe, and Israel
por: Mahtani, Reshma, et al.
Publicado: (2022)

Standardizing Quality Assessment of Observational Studies for Decision Making in Health Care
por: Brixner, Diana
Publicado: (2009)

Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015–2020
por: Arondekar, Bhakti, et al.
Publicado: (2022)

Real-World Treatment Patterns Among Patients With Metastatic Castration-Resistant Prostate Cancer: Results From an International Study
por: Barata, Pedro C, et al.
Publicado: (2023)

Real-World Treatment Trends Among Patients with Metastatic Castration-Sensitive Prostate Cancer: Results from an International Study
por: Barata, Pedro C, et al.
Publicado: (2023)

The impact of race on survival in metastatic prostate cancer: a systematic literature review
por: Freedland, Stephen J., et al.
Publicado: (2023)

Effectiveness and Cost-Effectiveness of Sequential Treatment of Patients with Chronic Myeloid Leukemia in the United States: A Decision Analysis
por: Rochau, Ursula, et al.
Publicado: (2015)

Application of Economic Analyses in U.S. Managed Care Formulary Decisions: A Private Payer's Experience
por: Watkins, John B., et al.
Publicado: (2006)

Real-World Evidence: Bridging Gaps in Evidence to Guide Payer Decisions
por: Roberts, Melissa H., et al.
Publicado: (2020)

All-Cause and Bleeding-Related Health Care Costs in Warfarin-Treated Patients with Atrial Fibrillation
por: Ghate, Sameer R., et al.
Publicado: (2011)

Communicating Healthcare Economic and Pre-approval Information With Healthcare Decision-Makers: Opportunities Following the 21st Century Cures Act and FDA Guidance
por: Niyazov, Alexander, et al.
Publicado: (2018)

Trends in outpatient emergency department visits during the COVID-19 pandemic at a large, urban, academic hospital system
por: Giannouchos, Theodoros V., et al.
Publicado: (2021)

Barriers to and Facilitators of Evidence-Based Decision Making at the Point of Care: Implications for Delivery Systems, Payers, and Policy Makers
por: O’Malley, Ann S., et al.
Publicado: (2016)

Improving patient-reported measures in oncology: a payer call to action
por: Schmidt, Theresa, et al.
Publicado: (2021)

Patient Perspectives on the Use of Digital Technology to Help Manage Cystic Fibrosis
por: Watanabe, Alexandre H., et al.
Publicado: (2023)

Managerial economics for decision making /
por: Adams, John, 1955-
Publicado: (2003)

Economic Decision-Making in Parrots
por: Krasheninnikova, Anastasia, et al.
Publicado: (2018)

Estimation of healthcare‐related charges in women with BRCA mutations and breast cancer
por: Biskupiak, Joseph, et al.
Publicado: (2021)

Payer perceptions and use of value assessment tools in the United States
por: Westrich, Kimberly, et al.
Publicado: (2023)

The economic burden of pulmonary arterial hypertension (PAH) in the US on payers and patients
por: Sikirica, Mirko, et al.
Publicado: (2014)

The Payer's Dilemma: Recognizing the Uncertainty of Clinical and Economic Evidence at Product Launch
por: Watkins, John B., et al.
Publicado: (2009)

Facilitating shared decision-making in oncology
por: Sobrero, Alberto, et al.
Publicado: (2023)

Perspectives to mitigate payer uncertainty in health technology assessment of novel oncology drugs
por: Solà-Morales, Oriol, et al.
Publicado: (2019)

Making the Case for Addressing Health Disparities: What Drives Providers and Payers?
por: Johnson, Margaret, et al.
Publicado: (2018)

Evolving Perceptions, Utilization, and Real-World Implementation Experiences of Oncology Monoclonal Antibody Biosimilars in the USA: Perspectives from Both Payers and Physicians
por: Yang, Jingyan, et al.
Publicado: (2021)

Hamilton’s rule in economic decision-making
por: Levy, Moshe, et al.
Publicado: (2022)

All-Cause and Incremental Per Patient Per Year Cost Associated with Chronic Hepatitis C Virus and Associated Liver Complications in the United States: A Managed Care Perspective
por: McAdam-Marx, Carrie, et al.
Publicado: (2011)

Treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer initiating first-line treatment in the US community oncology setting: a real-world retrospective observational study
por: Nadler, Eric, et al.
Publicado: (2020)

Hospitals and the Tax-Payer
Publicado: (1920)

Cannot write session to /tmp/vufind_sessions/sess_02c57l2ddm3riecve5osn9eqpg